Body Mass Index and Cardiorenal Outcomes in the EMPEROR-Preserved Trial: Principal Findings and Meta-Analysis with the DELIVER Trial

202433 citationsReviewhybrid Open Access

Authors

Naveed Sattar · University of Glasgow

Javed Butler · University of Mississippi Medical Center

Matthew M.Y. Lee · University of Glasgow

Josephine Harrington · Duke University

Abhinav Sharma · McGill University Health Centre

Faı̈ez Zannad · Inserm

Gerasimos Filippatos ·

Abstract

Empagliflozin treatment resulted in broadly consistent cardiac effects across the range of BMI in patients with HFpEF. SGLT2i treatment yields benefit in patients with HFpEF regardless of baseline BMI.

Topics & Keywords

Diabetes Treatment and Management Heart Failure Treatment and Management Cardiovascular Function and Risk Factors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Journal of Heart Failure

Volume 26, Issue 4, pp. 900-909

DOI: 10.1002/ejhf.3221

Field-Weighted Citation Impact: 11.86